Beta Cell Function and Related Pharmacodynamics of HMS5552 in T2DM Patients
NCT ID: NCT02386982
Last Updated: 2015-05-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
24 participants
INTERVENTIONAL
2015-03-31
2015-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Study to Access the Pharmacokinetics of HMS5552 in Hepatic Impaired Subjects and Healthy Volunteers
NCT04426708
Long-term Efficacy and Safety of HMS5552 add-on to Metformin in T2DM Subjects
NCT03141073
The Progress of Diabetes Mellitus After HMS5552 Treatment in Type 2 Diabetes Mellitus
NCT04091854
Drug-Drug Interaction Study of Glucokinase Activator HMS5552 and Metformin in T2DM
NCT02597400
Influence of HRS9531 on Pharmacokinetics of Metformin in Healthy Subjects
NCT06654960
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HMS5552 dose 1
HMS5552 75mg.Oral administration,twice per day.
HMS5552
HMS5552 dose 2
HMS5552 75mg.Oral administration,once per day.
HMS5552
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HMS5552
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has type 2 diabetes mellitus
* BMI 20 to 29kg/m2
* Willingness to adhere to the protocol requirement
Exclusion Criteria
* Received any antidiabetic drug within run-in or during screening
* Hepatic diseases
* Kidney diseases
* Clinical abnormal finding in EVG,labs and physical exams
* Women of child-bearing potential
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hua Medicine Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The 1st Betuhune Hospital of Jilin University
Changchun, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HMM0103
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.